News
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2024 Earnings CallAug 01, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Nvidia Stock Sank Today -- Is It Time to Buy the Dip?
Volatility continued for Nvidia (NASDAQ: NVDA) stock in Thursday's trading. The artificial intelligence (AI) leader's share ended the daily session down 6.7%, according to data from S&P Global
Biogen (BIIB) Q2 2024 Earnings Call Transcript
Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever
Great companies can deliver meaningful portfolio growth in a wide range of economic and market environments. From established companies to emerging businesses, the types of stocks you favor will
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
Pfizer (NYSE: PFE) has been a nightmare for many investors in recent years. At one point earlier this year, the big pharma stock was nearly 60% below its peak set in late 2021.
However, the
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
The anti-obesity drug market could be worth a staggering $100 billion, according to some analysts. That's a huge growth opportunity, and it's a reason why many top drugmakers in the world are
Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?
Just a couple of years ago, Pfizer's (NYSE: PFE) revenue was soaring thanks to sales of its coronavirus vaccine. In fact, the vaccine became the world's best-selling pharmaceutical product and even
Why Vertiv Holdings, Constellation Energy, and NuScale Power Surged Higher Today
Shares of data center infrastructure company Vertiv Holdings (NYSE: VRT), as well as nuclear power-oriented companies Constellation Energy (NASDAQ: CEG) and NuScale Power (NYSE: SMR) were rallying
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
Why ASML Holding Stock Was Climbing Today
Shares of ASML Holdings (NASDAQ: ASML), the world's largest provider of semiconductor manufacturing equipment, were moving higher today. They were buoyed by an analyst upgrade last night, news that
Pfizer (PFE) Q2 2024 Earnings Call Transcript
Merck (MRK) Q2 2024 Earnings Call Transcript
Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma
If you're looking to pick up some exposure to biotechs that are developing anti-obesity medications, there's no shortage of options. But with the substantial risk of investing in biotech in general
Is AT&T's Nearly 6%-Yielding Dividend Finally Safe?
AT&T (NYSE: T) has one of the highest dividend yields in the S&P 500. At nearly 6%, it's a lot higher than the market index's average of 1.3%. Sustainability concerns are a big driver of that high
EQS-News: Biotest increases sales in the first half of 2024 by 35% to Euro 372 million
The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.
Viking Therapeutics (NASDAQ: VKTX) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to second-quarter earnings, the
Prediction: This Will Be Pfizer's Next Big Move
Despite its impressive performance in 2020 and 2021, it's no secret that Pfizer (NYSE: PFE) is in the process of reinventing itself. Without much of the windfall from its coronavirus products
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
When a major player announces good news in a lucrative market like weight loss drugs, it's often enough to drive shares of competitors down based on the assumption that they will have struggles
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Biogen (NASDAQ: BIIB) built itself into a multiple sclerosis (MS) treatment giant over the years -- but as older blockbusters lost exclusivity, growth stalled. And last year, annual revenue dropped
AT&T Shares Climb on Subscriber Additions. Should Investors Add the Stock to Their Portfolios?
Share prices of AT&T (NYSE: T) were heading nicely higher after the wireless company saw solid subscriber additions and generated strong free cash flow when it reported its second-quarter results
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't
Is Viking Therapeutics a Millionaire-Maker Stock?
Among the hottest investments these days are pharma and biotech companies that make weight loss drugs. Demand for these products surpasses supply, and analysts predict that sales growth for the new
3 Surprisingly Underrated Stocks to Buy Right Now
The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely.
Three Motley Fool contributors think
EQS-Adhoc: Merck KGaA: Strong 2nd Quarter, Guidance raised
Better Buy: Abbott Laboratories vs. Intuitive Surgical
Investors looking for stocks that can go up want to turn their heads toward the medical technology industry. Demand for devices that enable minimally invasive surgical procedures and remote